$INO
INOVIO PHARMACEUTICALS, INC.

2017 Q4 Form 10-K Financial Statement

#000105572618000014 Filed on March 14, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $8.787M $2.645M $20.41M
YoY Change 3.21% -78.91% 229.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.030M $6.320M $6.170M
YoY Change 15.21% 9.72% 6.38%
% of Gross Profit
Research & Development $24.64M $25.51M $23.88M
YoY Change 3.05% -5.45% 21.64%
% of Gross Profit
Depreciation & Amortization $480.0K $1.160M $900.0K
YoY Change -42.17% 33.33% 13.92%
% of Gross Profit
Operating Expenses $31.68M $31.83M $30.05M
YoY Change 2.58% -2.77% 22.99%
Operating Profit -$22.89M -$29.19M -$9.636M
YoY Change 2.35% 44.51% -47.13%
Interest Expense $1.380M -$4.950M $160.0K
YoY Change -135.66% 783.93% -133.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.51M -$34.13M -$9.479M
YoY Change -18.01% 64.43% -49.32%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.51M -$34.13M -$9.479M
YoY Change -18.02% 64.43% -49.32%
Net Earnings / Revenue -244.74% -1290.75% -46.44%
Basic Earnings Per Share -$0.24 -$0.39 -$0.13
Diluted Earnings Per Share -$0.24 -$0.40 -$0.13
COMMON SHARES
Basic Shares Outstanding 90.30M shares 86.95M shares 75.41M shares
Diluted Shares Outstanding 87.09M shares 75.41M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.4M $141.9M $92.00M
YoY Change 21.56% 18.55% -31.6%
Cash & Equivalents $23.79M $23.28M $23.86M
Short-Term Investments $103.6M $118.6M $68.10M
Other Short-Term Assets $4.400M $5.500M $6.200M
YoY Change 33.33% 77.42% 100.0%
Inventory
Prepaid Expenses
Receivables $6.003M $6.237M $7.523M
Other Receivables $500.0K $1.000M $1.200M
Total Short-Term Assets $138.4M $154.6M $106.9M
YoY Change 11.05% 10.24% -27.77%
LONG-TERM ASSETS
Property, Plant & Equipment $18.32M $18.47M $15.02M
YoY Change 102.98% 105.45% 72.61%
Goodwill $10.51M $10.51M $10.51M
YoY Change 0.0% 0.0% 0.0%
Intangibles $6.010M $6.414M $6.818M
YoY Change -21.22% -20.2% -19.31%
Long-Term Investments $11.40M $11.50M $18.00M
YoY Change -42.42% -54.55% 239.62%
Other Assets $2.639M $2.197M $1.674M
YoY Change 24.9% 48.25% 26.23%
Total Long-Term Assets $48.88M $49.09M $51.98M
YoY Change -0.47% -9.62% -7.21%
TOTAL ASSETS
Total Short-Term Assets $138.4M $154.6M $106.9M
Total Long-Term Assets $48.88M $49.09M $51.98M
Total Assets $187.2M $203.7M $158.9M
YoY Change 7.79% 4.69% -22.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.20M $23.30M $17.30M
YoY Change 16.91% 39.52% 30.08%
Accrued Expenses $8.612M $7.920M $7.189M
YoY Change 35.23% 9.75% 43.59%
Deferred Revenue $1.175M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.41M $33.36M $27.38M
YoY Change -19.21% -19.36% -22.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $8.000M $7.800M
YoY Change -100.0% 33.33% 25.81%
Total Long-Term Liabilities $0.00 $8.000M $7.800M
YoY Change -100.0% 33.33% 25.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.41M $33.36M $27.38M
Total Long-Term Liabilities $0.00 $8.000M $7.800M
Total Liabilities $44.75M $41.56M $35.32M
YoY Change -11.08% -12.63% -15.69%
SHAREHOLDERS EQUITY
Retained Earnings -$523.4M -$501.9M -$467.7M
YoY Change 20.36% 22.82% 20.59%
Common Stock $90.36K $90.30K $77.63K
YoY Change 22.0% 22.07% 5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $142.4M $162.0M $123.4M
YoY Change
Total Liabilities & Shareholders Equity $187.2M $203.7M $158.9M
YoY Change 7.79% 4.69% -22.13%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$21.51M -$34.13M -$9.479M
YoY Change -18.02% 64.43% -49.32%
Depreciation, Depletion And Amortization $480.0K $1.160M $900.0K
YoY Change -42.17% 33.33% 13.92%
Cash From Operating Activities -$13.95M -$17.31M -$16.72M
YoY Change -6.44% -7.14% 26.0%
INVESTING ACTIVITIES
Capital Expenditures -$870.0K -$3.590M -$5.040M
YoY Change 1142.86% 663.83% 85.29%
Acquisitions
YoY Change
Other Investing Activities $15.46M -$50.57M -$1.390M
YoY Change 54.91% -629.53% -508.82%
Cash From Investing Activities $14.58M -$54.16M -$6.420M
YoY Change 46.98% -697.13% 169.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -120.0K 70.88M 24.10M
YoY Change -113.79% 1521.97% 871.77%
NET CHANGE
Cash From Operating Activities -13.95M -17.31M -16.72M
Cash From Investing Activities 14.58M -54.16M -6.420M
Cash From Financing Activities -120.0K 70.88M 24.10M
Net Change In Cash 510.0K -590.0K 960.0K
YoY Change -112.38% -88.65% -107.29%
FREE CASH FLOW
Cash From Operating Activities -$13.95M -$17.31M -$16.72M
Capital Expenditures -$870.0K -$3.590M -$5.040M
Free Cash Flow -$13.08M -$13.72M -$11.68M
YoY Change -11.86% -24.49% 10.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001055726
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90403853 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
608649117 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
INOVIO PHARMACEUTICALS, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016Q4 ino Accrued Subcontract Expenses
AccruedSubcontractExpenses
5475359 USD
CY2017Q4 ino Accrued Subcontract Expenses
AccruedSubcontractExpenses
3746937 USD
CY2015 ino Adjustment For Change In Fair Value Of Warrant Liability
AdjustmentForChangeInFairValueOfWarrantLiability
-721591 USD
CY2016 ino Adjustment For Change In Fair Value Of Warrant Liability
AdjustmentForChangeInFairValueOfWarrantLiability
0 USD
CY2017 ino Adjustment For Change In Fair Value Of Warrant Liability
AdjustmentForChangeInFairValueOfWarrantLiability
-806819 USD
CY2016Q2 ino Available For Sale Securities Ownership Percentage
AvailableForSaleSecuritiesOwnershipPercentage
0.164
CY2016 ino Cashless Exerciseof Warrants Value
CashlessExerciseofWarrantsValue
0 USD
CY2015 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
177561 USD
CY2016Q1 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-406249 USD
CY2016Q2 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-113775 USD
CY2016Q3 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
2690 USD
CY2016Q4 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
644888 USD
CY2016 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
127554 USD
CY2017Q1 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
116477 USD
CY2017Q2 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-312500 USD
CY2017Q3 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
423296 USD
CY2017Q4 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
579546 USD
CY2017 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
806819 USD
CY2015 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
-177561 USD
CY2016 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
-127554 USD
CY2017 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
-806819 USD
CY2015 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
2600467 USD
CY2016Q1 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
7480977 USD
CY2016Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-705527 USD
CY2016Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-958141 USD
CY2016Q4 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-4706522 USD
CY2016 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
1110787 USD
CY2017Q1 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-1608817 USD
CY2017Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
169096 USD
CY2017Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-5835741 USD
CY2017Q4 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
292798 USD
CY2017 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-6982664 USD
CY2016 ino Classof Warrantor Right Numberof Warrants Exercised
ClassofWarrantorRightNumberofWarrantsExercised
0 shares
CY2017 ino Classof Warrantor Right Numberof Warrants Exercised
ClassofWarrantorRightNumberofWarrantsExercised
0 shares
CY2015 ino Common Stock Issued For Intangible And Other Assets
CommonStockIssuedForIntangibleAndOtherAssets
0 USD
CY2016 ino Common Stock Issued For Intangible And Other Assets
CommonStockIssuedForIntangibleAndOtherAssets
4300000 USD
CY2017 ino Common Stock Issued For Intangible And Other Assets
CommonStockIssuedForIntangibleAndOtherAssets
0 USD
CY2016 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
-3117000 USD
CY2015 ino Comprehensive Income Loss Tax Expense Benefit
ComprehensiveIncomeLossTaxExpenseBenefit
-2098000 USD
CY2016 ino Comprehensive Income Loss Tax Expense Benefit
ComprehensiveIncomeLossTaxExpenseBenefit
0 USD
CY2017 ino Comprehensive Income Loss Tax Expense Benefit
ComprehensiveIncomeLossTaxExpenseBenefit
0 USD
CY2017 ino Convertible Preferred Stock Shares Issued Upon Conversion Conversion Price Per Share
ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
27.20
CY2017 ino Convertible Preferred Stock Threshold Consecutive Trading Days
ConvertiblePreferredStockThresholdConsecutiveTradingDays
30 day
CY2017 ino Convertible Preferred Stock Threshold Trading Days
ConvertiblePreferredStockThresholdTradingDays
20 day
CY2016Q4 ino Deferred Revenue From Affiliated Entity Current
DeferredRevenueFromAffiliatedEntityCurrent
407292 USD
CY2017Q4 ino Deferred Revenue From Affiliated Entity Current
DeferredRevenueFromAffiliatedEntityCurrent
174110 USD
CY2016Q4 ino Deferred Revenue From Affiliated Entity Noncurrent
DeferredRevenueFromAffiliatedEntityNoncurrent
86694 USD
CY2017Q4 ino Deferred Revenue From Affiliated Entity Noncurrent
DeferredRevenueFromAffiliatedEntityNoncurrent
0 USD
CY2016Q4 ino Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
989000 USD
CY2017Q4 ino Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
858000 USD
CY2017Q1 ino Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
1100000 USD
CY2015 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
339000 USD
CY2016 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
4269000 USD
CY2017 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
454000 USD
CY2015 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
-297000 USD
CY2016 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
-6456000 USD
CY2017 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
-165000 USD
CY2015Q2 ino Future Paymentstobe Receivedfrom Saleof Intangible Assets
FuturePaymentstobeReceivedfromSaleofIntangibleAssets
1000000 USD
CY2016Q4 ino Goodwill And Intangible Assets Gross
GoodwillAndIntangibleAssetsGross
35231244 USD
CY2017Q4 ino Goodwill And Intangible Assets Gross
GoodwillAndIntangibleAssetsGross
35231244 USD
CY2016Q4 ino Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
18141765 USD
CY2017Q4 ino Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
16523100 USD
CY2015 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
432174 USD
CY2016 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
139249 USD
CY2017 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
215423 USD
CY2015 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
-253000 USD
CY2016 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
-47000 USD
CY2017 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
-282000 USD
CY2015 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
-1537000 USD
CY2017 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
-3456000 USD
CY2015 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-49672 USD
CY2016 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-687827 USD
CY2017 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-319876 USD
CY2015 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
-771723 USD
CY2016 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
901772 USD
CY2017 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
333583 USD
CY2015 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
4000000 USD
CY2016 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
128000 USD
CY2017 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
4900000 USD
CY2015 ino Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax
2952201 USD
CY2016 ino Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax
-1268404 USD
CY2017 ino Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax
-1452431 USD
CY2017 ino Preferred Stock Conversion Daily Market Price Triggering Mandatory Conversion
PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion
72.00
CY2016Q4 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
1512424 USD
CY2017Q4 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
1846007 USD
CY2015 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
2598915 USD
CY2016 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
1640740 USD
CY2017 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
1342250 USD
CY2016Q2 ino Receivablefromsaleof Intangible Assets
ReceivablefromsaleofIntangibleAssets
2000000 USD
CY2015 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
779167 USD
CY2016Q1 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
137000 USD
CY2016Q2 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
499720 USD
CY2016Q3 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
574596 USD
CY2016Q4 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
189278 USD
CY2016 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
1400594 USD
CY2017Q1 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
233330 USD
CY2017Q2 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
176879 USD
CY2017Q3 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
129133 USD
CY2017Q4 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
226486 USD
CY2017 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
765828 USD
CY2015 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
26876533 USD
CY2016Q1 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
1796857 USD
CY2016Q2 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
1889988 USD
CY2016Q3 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
2327316 USD
CY2016Q4 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
476586 USD
CY2016 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
6490747 USD
CY2017Q1 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
4288586 USD
CY2017Q2 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
16358316 USD
CY2017Q3 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
351272 USD
CY2017Q4 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
7409214 USD
CY2017 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
28407388 USD
CY2017 ino Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm
P5Y10M15D
CY2017 ino Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
2300000 USD
CY2017Q4 ino Sharebased Compensation Arrangementby Sharebased Payment Award Options Expectedto Vest Outstanding Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber
7694870 shares
CY2017Q4 ino Tax Benefits Expired
TaxBenefitsExpired
13400000 USD
CY2017 ino Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Decrease In Deferred Tax Asset
TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDecreaseInDeferredTaxAsset
50000000 USD
CY2017 ino Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Decrease In Valuation Allowance
TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDecreaseInValuationAllowance
50200000 USD
CY2017 ino Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Income Tax Expense Benefit
TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit
-200000 USD
CY2015 ino Unrealized Gain On Investments Income Tax Benefit
UnrealizedGainOnInvestmentsIncomeTaxBenefit
2097766 USD
CY2016 ino Unrealized Gain On Investments Income Tax Benefit
UnrealizedGainOnInvestmentsIncomeTaxBenefit
0 USD
CY2017 ino Unrealized Gain On Investments Income Tax Benefit
UnrealizedGainOnInvestmentsIncomeTaxBenefit
0 USD
CY2017Q4 ino Working Capital
WorkingCapital
103000000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
19597787 USD
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23278798 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
19597787 USD
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
23278798 USD
CY2016Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
5920642 USD
CY2017Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
7564830 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
124597233 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15821511 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6003205 USD
CY2016Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
748355 USD
CY2017Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
486619 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6368389 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8611892 USD
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6531983 USD
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7997152 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5256181 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7106557 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1327968 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-117005 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
556718356 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
665775504 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6186848 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10479135 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13070962 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
870199 USD
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1377466 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1618665 USD
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6377633 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7897564 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8937494 shares
CY2016Q4 us-gaap Assets
Assets
173707166 USD
CY2017Q4 us-gaap Assets
Assets
187239270 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
138362160 USD
CY2015Q3 us-gaap Available For Sale Equity Securities Amortized Cost Basis
AvailableForSaleEquitySecuritiesAmortizedCostBasis
0 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
89406922 USD
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
105963923 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3878737 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2370208 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
453002 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
392571 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
85981187 USD
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
103986286 USD
CY2017 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
108000 USD
CY2017Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
42 investment
CY2017Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
16 investment
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
225148 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
164923 USD
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
851204 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40543982 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57632693 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19136472 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23786579 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17088711 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-38496221 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4650107 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
284091 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
284091 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74062370 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90357644 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74062370 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90357644 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
74062 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
90358 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26227877 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75120710 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89650745 USD
CY2015 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
84769 USD
CY2016 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2017 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2015 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-26143108 USD
CY2016 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-75120710 USD
CY2017 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-89650745 USD
CY2016Q4 us-gaap Cost Method Investments Fair Value Disclosure
CostMethodInvestmentsFairValueDisclosure
3777510 USD
CY2017Q4 us-gaap Cost Method Investments Fair Value Disclosure
CostMethodInvestmentsFairValueDisclosure
2325079 USD
CY2016Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
0 USD
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1594000 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2098000 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
174793 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4926000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
9104416 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14762720 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1175353 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
24766 USD
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
446646 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
877535 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5926424 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
317808 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
215853 USD
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-504000 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5452000 USD
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
297000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
118333000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95991000 USD
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
567000 USD
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8546000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1952000 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3783000 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1072579 USD
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
926943 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
95500000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
71665000 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1906000 USD
CY2016Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
5300000 USD
CY2017Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
7531000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4511000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3091000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
2231000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
2097000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
113407000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94039000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
175000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
24000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
175000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
124000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Investment In Noncontrolled Affiliates
DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
3624000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Investment In Noncontrolled Affiliates
DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
422000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1302000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1430000 USD
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
328000 USD
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
496000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
822000 USD
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015 us-gaap Depreciation
Depreciation
1048431 USD
CY2016 us-gaap Depreciation
Depreciation
1708498 USD
CY2017 us-gaap Depreciation
Depreciation
1850376 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5800000 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5900000 USD
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M15D
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M15D
CY2016 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2017 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y8M12D
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P0Y8M12D
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.61
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.55
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0110
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0175
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-722000 USD
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-134000 USD
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-807000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17089479 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18708144 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2133581 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1249584 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
492818 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
520414 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
547081 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1066251 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24717873 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24717873 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7628394 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6009729 USD
CY2015 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2016Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2016Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2016Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2016Q4 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2016 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2017Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2017Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2017Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2017Q4 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2017 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18063890 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5371613 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5799530 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5755603 USD
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6965517 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23892263 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7767589 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6169106 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6319775 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8033899 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28290369 USD
CY2016Q4 us-gaap Goodwill
Goodwill
10513371 USD
CY2017Q4 us-gaap Goodwill
Goodwill
10513371 USD
CY2016Q4 us-gaap Goodwill Gross
GoodwillGross
10513371 USD
CY2017Q4 us-gaap Goodwill Gross
GoodwillGross
10513371 USD
CY2015 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31200603 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73740339 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88205772 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2097766 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2098000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2100000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7882000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
29678000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-20965000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
676000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-495000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
50019000 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10920000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-25809000 USD
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-30872000 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2288000 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
113000 USD
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2332000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
396000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
501000 USD
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
2093000 USD
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2640000 USD
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4000 USD
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4000 USD
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1968000 USD
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1367000 USD
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
846000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6456581 USD
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6367965 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2829807 USD
CY2016Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
391596 USD
CY2016Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
191460 USD
CY2016 us-gaap Interest And Other Income
InterestAndOtherIncome
1257257 USD
CY2015 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
136640 USD
CY2016 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
907532 USD
CY2017 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-145636 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4497225 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8521899 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9818306 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
31627 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
714908 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-261736 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
593051 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3767906 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2243503 USD
CY2015 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-14166 USD
CY2016 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
849 USD
CY2017 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
150027 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10191840 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1527686 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13689322 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
196265 USD
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1442314 USD
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
526207 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
119284 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
831802 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
851847 USD
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
167123 shares
CY2016 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
140529 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7628394 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6009729 USD
CY2015 us-gaap Interest And Other Income
InterestAndOtherIncome
305071 USD
CY2016Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
333070 USD
CY2016Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
341131 USD
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
340341 USD
CY2017Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
300021 USD
CY2017Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
463346 USD
CY2017Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
509266 USD
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
1612974 USD
CY2015 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
348566 USD
CY2016 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
266290 USD
CY2017 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
319845 USD
CY2016Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
16052065 USD
CY2017Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
9069401 USD
CY2015Q4 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
773000 USD
CY2016Q4 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
523856 USD
CY2017Q4 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
0 USD
CY2016Q4 us-gaap Liabilities
Liabilities
50328746 USD
CY2017Q4 us-gaap Liabilities
Liabilities
44750461 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173707166 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
187239270 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43823027 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35405426 USD
CY2016Q4 us-gaap Minority Interest
MinorityInterest
96269 USD
CY2017Q4 us-gaap Minority Interest
MinorityInterest
96269 USD
CY2015 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
149559 USD
CY2016 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
149559 USD
CY2016Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.15
CY2017Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.15
CY2014Q2 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.85
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84351719 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7786942 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95690172 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54824107 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16271889 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27831144 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12438901 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62555052 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63208921 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-29187606 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8042820 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-18704711 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-20759338 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-26233470 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-73740339 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-23085907 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-9479116 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-34134570 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-21506179 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-88205772 USD
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
84769 USD
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29909197 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73740339 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89012591 USD
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2015 us-gaap Operating Expenses
OperatingExpenses
74855813 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
23560773 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
24430331 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
32735946 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
30877248 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
111604298 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
32310093 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
30047857 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
31830014 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
31675023 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
125862987 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-34283702 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15450618 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18226540 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20195483 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-22363296 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-76235937 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21933908 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9635733 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29185471 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-22887789 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-83642901 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
38904000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3251000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4052000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3979000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3891000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3756000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
19975000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1600000 USD
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2400000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1669803 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
3969879 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2113147 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2639354 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7528 USD
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-111967 USD
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7458 USD
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2017 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
139000 USD
CY2017 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
215000 USD
CY2015 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
1000000 USD
CY2016 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
1000000 USD
CY2015 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1200000 USD
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2781544 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2738470 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10293902 USD
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
63526830 USD
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57317671 USD
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
95700144 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
23 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
23 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
23 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
23 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1749059 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2600906 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81902363 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6295761 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94347922 USD
CY2015 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-149559 USD
CY2016 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-149559 USD
CY2017 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2015 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
1000000 USD
CY2016 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
1000000 USD
CY2017 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
1000000 USD
CY2015 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
10484267 USD
CY2016 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
76528030 USD
CY2017 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
77162902 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
552000 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1800000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2300000 USD
CY2015 us-gaap Profit Loss
ProfitLoss
-29102837 USD
CY2016 us-gaap Profit Loss
ProfitLoss
-73740339 USD
CY2017 us-gaap Profit Loss
ProfitLoss
-88205772 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14281627 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25426733 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9025446 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18320176 USD
CY2015 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0 USD
CY2016Q1 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0 USD
CY2016Q2 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0 USD
CY2016Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
227903 USD
CY2016Q4 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
112660 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25510239 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24641124 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98572618 USD
CY2016 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
340563 USD
CY2017Q1 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
614036 USD
CY2017Q2 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
1079282 USD
CY2017Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
707922 USD
CY2017Q4 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
171091 USD
CY2017 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
2572331 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57791923 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18189160 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19630801 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26980343 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23911731 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88712035 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24542504 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23878751 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434838235 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-523356317 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
12916411 USD
CY2016Q1 us-gaap Revenue From Grants
RevenueFromGrants
6176298 USD
CY2016Q2 us-gaap Revenue From Grants
RevenueFromGrants
3814083 USD
CY2016Q3 us-gaap Revenue From Grants
RevenueFromGrants
9410648 USD
CY2016Q4 us-gaap Revenue From Grants
RevenueFromGrants
7735428 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
27136457 USD
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
5240233 USD
CY2017Q2 us-gaap Revenue From Grants
RevenueFromGrants
2797647 USD
CY2017Q3 us-gaap Revenue From Grants
RevenueFromGrants
1456216 USD
CY2017Q4 us-gaap Revenue From Grants
RevenueFromGrants
980443 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
10474539 USD
CY2015 us-gaap Revenues
Revenues
40572111 USD
CY2016Q1 us-gaap Revenues
Revenues
8110155 USD
CY2016Q2 us-gaap Revenues
Revenues
6203791 USD
CY2016Q3 us-gaap Revenues
Revenues
12540463 USD
CY2016Q4 us-gaap Revenues
Revenues
8513952 USD
CY2016 us-gaap Revenues
Revenues
35368361 USD
CY2017Q1 us-gaap Revenues
Revenues
10376185 USD
CY2017Q2 us-gaap Revenues
Revenues
20412124 USD
CY2017Q3 us-gaap Revenues
Revenues
2644543 USD
CY2017Q4 us-gaap Revenues
Revenues
8787234 USD
CY2017 us-gaap Revenues
Revenues
42220086 USD
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
40572111 USD
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
35368361 USD
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
42220086 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
6186848 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
10479135 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
13070962 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
456000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3500000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
519000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
83696 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
69570 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
200501 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
446461 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.49
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1788121 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.60
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.59
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.33
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6806183 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7694870 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.81
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.77
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.18
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.89
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.01
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.67
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.62
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5444771 shares
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
7694870 shares
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2300000 USD
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.68
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.77
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y6M27D
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
85629412 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
103638844 USD
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
452973 shares
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4300000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
81902363 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6295761 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94347922 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2598915 USD
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1640740 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1342250 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
123282151 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
142392540 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
111537594 USD
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
175933053 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123378420 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
142488809 USD
CY2015 us-gaap Straight Line Rent
StraightLineRent
-383584 USD
CY2016 us-gaap Straight Line Rent
StraightLineRent
16728 USD
CY2017 us-gaap Straight Line Rent
StraightLineRent
-3608881 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2759000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5455000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6855000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8313000 USD
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
74000 USD
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
615000 USD
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1183000 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1532000 USD
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2081000 USD
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
217000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
7100000 USD
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1167614 USD
CY2017Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
360795 USD
CY2017Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
361000 USD
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68365265 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73214766 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81918022 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68198142 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73214766 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81777493 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments, that potentially subject the Company to concentrations of credit risk, consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</font></div></div>
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), a clinical stage biopharmaceutical company, develops active SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> DNA immunotherapies and vaccines focused on preventing and treating cancers and infectious diseases. Inovio&#8217;s DNA-based immunotherapies, in combination with proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> delivery devices, are intended to generate optimal antigen production </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo, </font><font style="font-family:inherit;font-size:10pt;">in particular functional CD8+ killer T cell and antibody responses, to fight target diseases.&#160; Inovio&#8217;s synthetic products are based on its SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;immunotherapy design.&#160; The Company and its collaborators are currently conducting or planning clinical programs of its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung and pancreatic cancers; hepatitis B virus ("HBV"); HIV; Ebola; Middle East Respiratory Syndrome ("MERS"); and Zika virus.&#160; &#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company's partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc. ("GeneOne"), Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the&#160;Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), United States Military HIV Research Program (&#8220;USMHRP&#8221;), U.S. Army Medical Research Institute of Infectious Diseases (&#8220;USAMRIID&#8221;), National Institutes of Health ("NIH"), HIV Vaccines Trial Network (&#8220;HVTN&#8221;)&#160;and Defense Advanced Research Projects Agency (&#8220;DARPA&#8221;). </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in accordance with United States generally accepted accounting principles requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in the business or as new information becomes available.</font></div></div>

Files In Submission

Name View Source Status
0001055726-18-000014-index-headers.html Edgar Link pending
0001055726-18-000014-index.html Edgar Link pending
0001055726-18-000014.txt Edgar Link pending
0001055726-18-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ino-12312017x10k.htm Edgar Link pending
ino-12312017x10kex1012.htm Edgar Link pending
ino-12312017x10kex211.htm Edgar Link pending
ino-12312017x10kex231.htm Edgar Link pending
ino-12312017x10kex311.htm Edgar Link pending
ino-12312017x10kex312.htm Edgar Link pending
ino-12312017x10kex321.htm Edgar Link pending
ino-20171231.xml Edgar Link completed
ino-20171231.xsd Edgar Link pending
ino-20171231_cal.xml Edgar Link unprocessable
ino-20171231_def.xml Edgar Link unprocessable
ino-20171231_lab.xml Edgar Link unprocessable
ino-20171231_pre.xml Edgar Link unprocessable
inoperformance2017a01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending